Neural reflex mechanisms, such as the baroreflex, are involved in the regulation of cardiovascular system activity. Previous results from our group have shown that glutamatergic synapses in the ventral portion of the medial prefrontal cortex (vMPFC) modulate baroreflex activity. Moreover, glutamatergic neurotransmission in the vMPFC can be modulated by the endocannabinoids system (eCBs), particularly the endocannabinoid anandamide, through pre-synaptic CB 1 receptor activation. Therefore, in the present study we investigated eCBs receptors that are present in the vMPFC, and more specifically whether CB 1 receptors modulate baroreflex activity. We found that Taken together, our results support the view that the eCBs in the vMPFC is involved in the modulation of baroreflex activity through the activation of CB 1 receptors, which modulate local glutamate release.
Introduction
The medial prefrontal cortex (MPFC) is a limbic structure that is involved in the modulation of autonomic responses exerting influence on the cardiovascular system in rats (44, 57) . The ventral portion of the MPFC (vMPFC), which is compounded by the infralimbic (IL), prelimbic (PL) and dorsal peduncular (DP) cortices (41, 61) , is involved in the modulation of baroreflex activity (49, 56) .
Glutamatergic terminals and ionotropic glutamate receptors were reported in the vMPFC of rats (18, 36) . Furthermore, a previous study from our group showed that local injection of L-glutamate into the vMPFC evokes an activation of both sympathetic and parasympathetic activities on the heart of unanesthetized rats (48) . Moreover, the glutamatergic system present in the vMPFC is involved in baroreflex modulation (45) .
In the central nervous system (CNS), the endocannabinoid anandamide is synthesized on-demand in post-synaptic neurons, after calcium influx increase (13, 42) .
Anandamide immediately diffuses to the synaptic cleft, activating CB1cannabinoid receptors, which are located in pre-synaptic terminals (59) . The action of anandamide is limited by its re-uptake through a putative anandamide transporter, being subsequently metabolised by the intracellular enzyme Fatty Acid Amide Hydrolase (FAAH) that is located in post-synaptic neurons (14, 43) . These two mechanisms, which cooperate to attenuate anandamide signaling in the CNS, can be pharmacologically inhibited by drugs such as AM404 (anandamide re-uptake inhibitor) and URB597 (FAAH inhibitor).
The CB1cannabinoid receptor is one of the most abundant G protein-coupled receptors in the brain and is expressed at high levels in the hippocampus, cortex, and basal ganglia (22, 23, 54) . Moreover, CB 1 receptors are predominantly localized presynaptically, where they modulate neurotransmitter release (25, 58, 60) . Several studies have shown that central nervous system glutamatergic neurotransmission can be modulated by the endocannabinoid system (eCBs) through CB 1 receptors (5, 15, 20) .
The presence of CB 1 receptors in the vMPFC of rats has been demonstrated (19, 22, 23, 34) , and their inhibition by a CB 1 antagonist increasing the release of glutamate (5), thus suggesting that the eCBs, through CB 1 receptors, inhibits glutamatergic synaptic transmission in the vMPFC.
Thus, if glutamatergic neurotransmission is involved in vMPFC-related modulation of the baroreflex, and CB 1 receptors can modulate the release of glutamate in the vMPFC, there is also the possibility that vMPFC CB 1 receptors could modulate baroreflex activity. Therefore, in the present study we evaluated the involvement of the eCBs present in the vMPFC in the modulation of cardiac baroreflex responses to blood pressure changes.
Materials and Methods

Ethical approval and animals
Experimental procedures were carried out following protocols approved by the Ethical Review Committee of the School of Medicine of Ribeirão Preto (Protocol number 128/2010), which comply with the Guiding Principles for Research Involving Animals and Human Beings of the American Physiological Society. Male Wistar rats weighing 230-270 g were used in the present experiments. They were kept under a 12:00 h lightdark cycle (lights on between 6:00 AM and 6:00 PM) and had free access to water and standard rat food.
Animal preparation
Four days before the experiment, rats were anesthetized with tribromoethanol (250 mg/kg, i.p., Sigma, St. Louis, Missouri, USA). After a local anesthesia with 2% lidocaine, the skull was surgically exposed and stainless steel guide cannulae (26G) were bilaterally implanted into the vMPFC using a stereotaxic apparatus (Stoelting, Wood Dale, Illinois, USA). Stereotaxic coordinates for cannulae implantation in the vMPFC were selected from the rat brain atlas of Paxinos and Watson (2007) and were: AP= +3.3 mm, L= 2.7 mm from the medial suture and V= -3.2 mm from the skull, with a lateral inclination of 24°. Cannulae were fixed to the skull with dental cement and one metal screw. After the surgery, animals were treated with a polyantibiotic preparation of streptomycins and penicillins (i.m., Pentabiotico®, Fort Dodge, Campinas, São Paulo, Brazil) to prevent infection and also with the non-steroidal anti-inflammatory drug flunixine meglumine (s.c., Banamine®, Schering Plough, Cotia, São Paulo, Brazil) for post-operative analgesia.
One day before the experiment, rats were again anesthetized with tribromoethanol (250 mg/kg, i.p.) and a catheter (a 4 cm segment of PE-10 that was heat-bound to a 13 cm segment of PE-50, Clay Adams, Parsippany, New Jersey, USA) was inserted into the abdominal aorta through the femoral artery, for blood pressure recording. A second catheter was implanted into the femoral vein for the infusion of vasoactive drugs to evoke arterial blood pressure changes. Both catheters were tunneled under the skin and exteriorized on the animal's dorsum. After the surgery, the treatment with antiinflammatory drugs was repeated.
Measurement of cardiovascular responses
The pulsatile arterial pressure of freely moving animals was recorded using an HP-7754A preamplifier (Hewlett Packard, Palo Alto, California, USA) and an acquisition board (Biopac M-100, Goleta, California, USA) connected to a computer. Mean arterial pressure (MAP) and heart rate (HR) values were derived from pulsatile recordings and processed on-line.
Drug injection
The needles (33G, Small Parts, Miami Lakes, FL, USA) used for the microinjection of drugs into the vMPFC were 1 mm longer than the guide cannulae and were connected to a 1-µL syringe (7002-H, Hamilton Co., Reno, NV, USA) through a segment of PE-10 tubing. The needle was carefully inserted into the guide cannula and drugs were injected in a final volume of 200 nL over a 5-s period. After a 30-s period, the needle was removed and inserted into the second guide cannula for the microinjection into the contralateral vMPFC.
Baroreflex stimulation
The baroreflex was activated by an intravenous infusion of phenylephrine (50 μg/kg; 0.34 mL/min) or sodium nitroprusside (SNP; 50 μg/kg; 0.8 mL/min) using an infusion pump (KD Scientific, Holliston, MA, USA). Either phenylephrine or SNP infusions lasted 50-60 -s and caused blood pressure increase or decreases, respectively (4, 49).
Method of baroreflex evaluation
Baroreflex curves were constructed matching MAP variations with HR responses.
Paired values of MAP (ΔMAP) and HR (ΔHR) variations were plotted to generate sigmoid curves for each rat, which were used to determine the baroreflex activity (49) .
To analyze bradycardic and tachycardic responses separately, HR values matching 10, 20, 30 and 40 mmHg of MAP changes were calculated (3, 11) . Values were plotted to create linear regression curves for each rat and their slopes were compared to test possible changes in the baroreflex gain.
Drugs
The following drugs were used: the anandamide transporter inhibitor 4- 
Experimental protocols
All groups of animals used in our study received three sets of phenylephrine or SNP infusion to determine control values of baroreflex activity. In the sequence, the first 
Histological procedure
At the end of experiments, rats were anesthetized with urethane (1.25 g/kg, i.p.) and 200 nL of 1% Evan's blue dye was bilaterally injected into the vMPFC as a marker of injection sites. The chest was surgically opened, the descending aorta occluded, the right atrium severed and the brain was perfused through the left ventricle with 10%
formalin, Brains were post-fixed for 24 h at 4 °C, and 40-µm sections were cut using a cryostat (CM-1900, Leica, Wetzlar, Germany). The actual placement of the injection needle was verified in serial sections, according to the rat brain atlas of Paxinos and
Watson (41).
Data analysis
Baseline cardiovascular values, before and after pharmacological treatment of the vMPFC, were compared using the Student's t test. The baroreflex was analyzed using sigmoid curves, which were characterized as 4 parameters: (i) P1 (bpm) lower heart rate plateau and P2 (bpm) upper heart rate plateau; (ii) heart rate range (bpm), difference between upper and lower plateau levels; (iii) median blood pressure (BP 50 , mmHg), which is the mean arterial pressure at 50% of the heart rate range; and (iv) average gain (G, bpm/ mmHg), which is the average slope of the curves between +1 and -1 standard derivations from BP 50 (21, 29). Significant differences among sigmoid curves or linear regression parameters were analyzed using one-way ANOVA followed by the Dunnett's post hoc test. The slope of linear regression curves (∆ HR vs ∆ MAP) before, 10 and 60 min after the microinjection of each treatment was determined and results were analyzed to detect alterations in the cardiac baroreflex gain, using one-way ANOVA followed by the Dunnett´s post hoc test. Results of statistical tests with P<0.05 were considered significant. 
Results
CB1 receptor antagonist AM251
Bilateral microinjection of three doses of the CB1 receptor antagonist AM251 into the vMPFC did not affect the basal levels of either MAP or HR (Table 1) . Non-linear regression analysis indicated that a dose of 10 pmol (n= 6) had no effect on the nonlinear baroreflex parameters analyzed ( Fig. 2 and Table 2 ), while doses of 100 (n= 8)
and 300 pmol (n= 10) were able to increase the baroreflex activity ( Fig. 2 and Table 2 ).
Moreover, we observed a significant correlation between doses and the increase in the baroreflex activity (P1: r 2 =0.67, df=20, P < 0.05; P2: r 2 =0.78, df=20, P < 0.05; Range: r 2 =0.5, df=20, P < 0.05 and Gain: r 2 =0.5, df=20, P < 0.05). The effect of AM251 on the baroreflex activity was reverted after 60 min ( Fig. 2 and Table 2 ).
For further analysis of the baroreflex response, the effect of either MAP increases or decreases on the HR that were observed before and after bilateral microinjection of different doses of AM251 into the vMPFC was analyzed separately using linear regression ( Fig. 2) . Again a dose of 10 pmol did not affect the linear regression slope of both bradycardic (before= -1.78 ± 0.27 and 10 min after= -1.97 ± 0.29 bpm/ mmHg; The group of animals that received a microinjection of 300 pmol of AM251 was subdivided into animals that received the microinjection into the PL or into the IL. 
Anandamide transporter inhibitor AM404
Bilateral microinjection of two doses of the anandamide transporter inhibitor AM404
into the vMPFC did not affect the basal levels of either MAP or HR (Table 1 ). The analysis of nonlinear regression indicated that 50 pmol of AM404 (n= 5) did not affect the baroreflex activity ( Fig. 3 ; Table 3 ). Moreover, linear regression analysis showed that the slope of both bradycardic (before= -1.78 ± 0.27 and 10 min after= -1.97 ± 0.29 bpm/ mmHg; F (2,14) = 1.14; P> 0.05) and tachycardic (before= -2.70 ± 0.30 and 10 min after= -2.60 ± 0.60 bpm/ mmHg; F (2, 14) = 0.25; P> 0.05) responses were not affected by the same dose of AM404 (Fig. 3) . However, a dose of 100 pmol (n= 6) decreased the baroreflex activity evaluated in nonlinear regression, which was normalized after 60 min ( Fig. 3 and Table 3 ). Similarly, this dose also decreased the slope of the linear regression of both bradycardic (before= -2.06 ± 0.21 and 10 min after= -1.28 ± 0.14 bpm/ mmHg, F (2,17) = 5.19; P< 0.05) and tachycardic (before= -2.96 ± 0.22 and 10 min after= -2.21 ± 0.20 bpm/ mmHg; F (2,17) = 3.14; P< 0.05) responses (Fig. 3) . The recovery of the baroreflex was observed 60 min after administration of AM404 (bradycardia: -2.11 ± 0.24 bpm/ mmHg; P> 0.05 and tachycardia: -2.73 ± 0.23 bpm/ mmHg; P> 0.05) (Fig. 3) .
Finally, the decrease of baroreflex activity, evaluated in nonlinear regression, evoked by a dose of 100 pmol of AM404 was inhibited by vMPFC pre-treatment with 10 pmol of the CB1 receptor antagonist AM251 (n= 5) ( Fig. 3 and table 3 ). In the same way, the decrease of slope observed in both bradycardic (before= -1.71 ± 0.16 and 10 min after= -1.66 ± 0.11 bpm/ mmHg; F (2, 14) = 0.33; P> 0.05) and tachycardic (before= -3.00 ± 0.20 and 10 min after= -2.85 ± 0.08 bpm/ mmHg; F (2,14)= 1.33; P> 0.05 ) responses were inhibited by treatment with AM251 (Fig. 3) .
Enzyme that degrades anandamide inhibitor URB597
Bilateral microinjection into the vMPFC of an inhibitor of the enzyme that degrades anandamide URB597 did not affect the basal levels of either MAP or HR (Table 1) .
Nonlinear regression analysis indicated that 100 pmol of URB597 (n= 6) decreased the baroreflex activity, which was normalized after 60 min (Fig. 4 and Table 4 (Fig. 4) . Recovery of the baroreflex was observed 60 minutes after administration of URB597 (bradycardia: -2.05 ± 0.10 bpm/ mmHg; P> 0.05 and tachycardia: -2.29 ± 0.18 bpm/ mmHg; P> 0.05) (Fig. 4) .
Similar to the observation with AM404, an anandamide transporter inhibitor, the reduction of baroreflex activity, evaluated in non-linear regression, evoked by URB597
was inhibited by vMPFC pre-treatment with 10 pmol of the CB1 receptor antagonist AM251 (n= 7) (Fig. 4 and table 4) . Similarly, the decrease of slope observed in both (Fig. 4) .
Discussion
The present study showed that the vMPFC eCBs has an influence on baroreflex activity. This is supported by the observation that a blockade of CB1 receptors increased baroreflex activity, as well as by the observation that increases in endogenous anandamide levels, which were evoked by inhibition of either the enzyme that degrades The analyses of baroreflex sigmoid curves generated before and 10 min after bilateral microinjection of the CB1 receptor antagonist AM251 at doses of 100 and 300 pmol, but not 10 pmol, resulted in an increase of the lower HR plateau (P1), upper HR plateau (P2), ΔP (range HR) and the slope of the sigmoid curve (G), without changes in BP 50 .
The P1 rise was due to an increase in the baroreflex parasympathetic activity, which strengthened the reflex bradycardia in response to blood pressure increases (21). The P2
rise was a consequence of the increased sympathetic activity, which promoted an enhancement in the tachycardic response associated with a reduction in the blood pressure (21), while the increase in the ΔP was result of P1 and P2 increases (9) .
Moreover, these increases in both the parasympathetic and sympathetic baroreflex produced an opposite effect on baroreflex activity, which was characterized by a decrease of P1, P2, ΔP and G sigmoidal parameters. Moreover, in the linear regression analyses we observed a decrease in both tachycardic and bradycardic responses associated with blood pressure variation. These effects on baroreflex, evoked by increased anandamide levels in the vMPFC, were inhibited by a pre-administration of an ineffective dose of AM251. Therefore, our data show that CB1 receptor activation in the vMPFC has an inhibitory influence on baroreflex activity, and that the increase of anandamide levels in the vMPFC decreases the baroreflex response, which is dependent on CB1 receptors. On the other hand, the blockade of CB1 receptors increases the baroreflex response. Together, these findings suggest that activation of CB 1 receptors in the vMPFC could be modulating the baroreflex response, reinforcing the proposed role of this brain area in this process (49, 56) .
It has been described that glutamatergic neurotransmission in the central nervous system can be modulated by the eCBs (15, 20) . In the vMPFC, CB 1 receptors are localized presynaptically in glutamatergic neuron terminations (5, 12) and a CB 1 receptor agonist decreases glutamate release, whereas a CB 1 receptor antagonist increases it (5).
Moreover, systemic administration of a CB 1 receptor antagonist increases neuronal activation in the vMPFC (2). These results suggest that glutamatergic releases in the vMPFC are tonically inhibited by endogenous cannabinoids through CB 1 receptors. In agreement with these data, it was described that antagonism of NMDA glutamatergic receptors in the vMPFC decreases parasympathetic baroreflex activity (45), as we observed with increases of CB 1 receptor activation by endogenous anandamide.
However, the role of NMDA glutamatergic receptors in the vMPFC on sympathetic baroreflex activity was not investigated and more experiments are necessary. Finally, findings from our group showed that the glutamatergic system present in the vMPFC is involved with activation of the cardiac sympathetic and parasympathetic nervous system (46) . Together, the previous results and the present findings support the idea that the eCBs could play an important role in baroreflex activity by controlling glutamatergic synaptic transmission in the vMPFC.
This interaction between glutamate and the eCBs in the vMPFC has been described previously. The systemic administration of CB 1 receptor agonists promotes anxiolyticlike effects associated with increases of the anandamide levels in the vMPFC (40) . In addition, results from our group showed that expression of mRNA for CB 1 receptors in the vMPFC is increased in animals exposed to a protocol of contextual fear 
Perspective and Significance
In summary, the present results suggest that eCB mediated neurotransmission in the vMPFC modulates baroreflex activity. They also agree with the proposal that the eCBs acts to modulate glutamate release and suggest that the vMPFC could be a brain site for baroreflex modulation during defensive behaviour. Table 2 Parameters derived from the sigmoidal curve generated before, 10 and 60 min after bilateral microinjection of 10 pmol (n= 6), 100 pmol (n= 8) or 300 pmol (n= 10) of AM251 into the vMPFC. 
Table 3
Parameters derived from the sigmoidal curve generated before, 10 min and 60 min after bilateral microinjection of 50 pmol (n= 5) or 100 pmol (n= 6) of AM404 and 100 pmol of AM404 after 10 pmol of AM251 (n= 6) into the vMPFC. F (2, 14) = 1.73 F (2, 14) = 1.40 F (2, 14) = 0.18 F (2, 14) = 0.25 F (2, 14) = 0.16 Before -1.83 ± 0.06 -90 ± 7 81 ± 9 171 ± 15 -3.4 ± 0.8 10 min -2.02 ± 0.09 -81 ± 9 73 ± 12 154 ± 20 -2.9 ± 0.9 60 min -1.94 ± 0.05 -85 ± 11 75 ± 6 160 ± 15 -2.7 ± 0.8
AM404 100
F (2, 17) Before -2.10 ± 0.10 -78 ± 5 110 ± 7 187 ± 11 -5.8 ± 0.6 10 min -1.38 ± 0.08* -49 ± 5* 81 ± 7* 129 ± 10* -6.1 ± 0.9 60 min -2.28 ± 0.07 -82 ± 8 104 ± 8 186 ± 13 -5.7 ± 1.1
AM251 + AM404
F (2, 14) = 2.03 F (2, 14) = 0.64 F (2, 14) = 1.59 F (2, 14) = 0.36 F (2, 14) = 0.10 Before -1.88 ± 0.09 -65 ± 6 110 ± 5 175 ± 9 -9.4 ± 2.1 10 min -1.68 ± 0.06 -59 ± 4 104 ± 3 1 7 1± 6 -9.6 ± 1.0 60 min -1.82 ± 0.06 -67 ± 6 100 ± 4 164 ± 11 -8.7 ± 1.2 Table 4 Parameters derived from the sigmoidal curve generated before, 10 min and 60 min after bilateral microinjection of 100 pmol of URB597 (n = 6) and the same dose after 10 pmol of AM251 (n= 7) into the vMPFC. 
